Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study

Basit Öğe Kaydı
dc.contributor.authorInal, A.
dc.contributor.authorKos, F. T.
dc.contributor.authorAlgin, E.
dc.contributor.authorYildiz, R.
dc.contributor.authorBerk, V.
dc.contributor.authorUnek, I. Tugba
dc.contributor.authorColak, D.
dc.date.accessioned2024-04-24T17:37:50Z
dc.date.available2024-04-24T17:37:50Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: The majority of patients with pancreatic cancer present with advanced disease. Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of this study was to analyse prognostic factors for OS in advanced pancreatic cancer patients treated with first-line palliative chemotherapy with gemcitabine alone or gemcitabine plus cisplatin. Methods: We retrospectively reviewed 343 locally advanced or metastatic pancreatic cancer patients who were treated with gemcitabine or gemcitabine plus cisplatin as first-line chemotherapy between December 2000 and June 2011. Fifteen potential prognostic variables were chosen for analysis. Univariate and multivariate analyses were conducted to identify prognostic factors associated with OS. Univariate and multivariate statistical methods were used to determine prognostic factors. Results: Among the 15 variables of univariate analysis, 6 were identified to have prognostic significance: stage (p<0.001), cholestasis (p=0.02), weight loss, prior pancreatectomy, serum CEA level (p<0.001) and serum CA19-9 level (p<0.001). In addition, age, chemotherapy and liver metastasis were of borderline significance (p=0.06). Multivariate analysis (Cox proportional hazard model) included the 6 significant prognostic factors of univariate analysis and showed that stage was independent prognostic factor for OS, as were weight loss, and serum CEA level. Conclusion: Stage, weight loss, and serum CEA level were identified as important prognostic factors for OS in advanced pancreatic cancer patients. These findings may also facilitate pretreatment prediction of OS and can be used for selecting patients for treatment.en_US
dc.identifier.endpage105en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue1en_US
dc.identifier.pmid22517701
dc.identifier.scopus2-s2.0-84859823703
dc.identifier.scopusqualityQ3
dc.identifier.startpage102en_US
dc.identifier.urihttps://hdl.handle.net/11468/21208
dc.identifier.volume17en_US
dc.identifier.wosWOS:000302503700016
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal of Buon
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCanceren_US
dc.subjectGemcitabineen_US
dc.subjectPancreasen_US
dc.subjectPrognosisen_US
dc.titlePrognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter studyen_US
dc.titlePrognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu